Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

ClinicalTrials.gov ID: NCT02719574

Public ClinicalTrials.gov record NCT02719574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 16, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Study identification

NCT ID: NCT02719574
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Forma Therapeutics, Inc.; Industry
Enrollment: 336 participants

Conditions and interventions

Conditions

Interventions

Azacitidine Drug
Cytarabine Drug
FT-2102 (olutasidenib) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2016
Primary completion: Dec 27, 2023
Completion: Jan 23, 2024
Last update posted: Jun 25, 2025

2016 – 2024

United States locations

U.S. sites: 19
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
UCLA Medical Center	Los Angeles	California	90024	—
UC Davis Comprehensive Cancer Center	Sacramento	California	95817	—
Yale University	New Haven	Connecticut	06510	—
University of Miami	Miami	Florida	33136	—
Emory Winship Cancer Institute	Atlanta	Georgia	30322	—
Northwestern University Feinberg School of Medicine	Chicago	Illinois	60611	—
University of Maryland Greenebaum Cancer Center	Baltimore	Maryland	21201	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
New York Medical College	Hawthorne	New York	10532	—
Columbia University Medical Center	New York	New York	10032	—
Cornell University Weill Medical College	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27705	—
The Ohio State University	Columbus	Ohio	43210	—
Oregon Health & Science University	Portland	Oregon	97229	—
Sarah Cannon Research Institute - Tennessee Oncology	Nashville	Tennessee	37203	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02719574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 25, 2025 · Synced May 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02719574 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →